FY2025 EPS Estimates for Alector Decreased by Analyst

Alector, Inc. (NASDAQ:ALEC) – Analysts at Cantor Fitzgerald lowered their FY2025 EPS estimates for Alector in a report released on Wednesday, October 22nd. Cantor Fitzgerald analyst P. Stavropoulos now expects that the company will post earnings of ($1.63) per share for the year, down from their previous estimate of ($1.53). Cantor Fitzgerald has a “Neutral” rating on the stock. The consensus estimate for Alector’s current full-year earnings is ($1.88) per share. Cantor Fitzgerald also issued estimates for Alector’s FY2026 earnings at ($0.81) EPS.

Alector (NASDAQ:ALEC) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.15. The firm had revenue of $7.87 million for the quarter, compared to analyst estimates of $2.76 million. Alector had a negative net margin of 142.10% and a negative return on equity of 112.06%. Alector has set its FY 2025 guidance at EPS.

Several other research firms have also recently weighed in on ALEC. Weiss Ratings reiterated a “sell (d-)” rating on shares of Alector in a research report on Friday. Cowen cut shares of Alector to a “hold” rating in a research report on Wednesday. Mizuho set a $1.50 price objective on shares of Alector and gave the stock a “neutral” rating in a research report on Wednesday. BTIG Research cut shares of Alector from a “buy” rating to a “neutral” rating in a research report on Wednesday. Finally, William Blair cut shares of Alector from an “outperform” rating to a “market perform” rating in a research report on Wednesday. One research analyst has rated the stock with a Buy rating, seven have given a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Reduce” and a consensus price target of $3.00.

Alector Trading Up 2.0%

Alector stock opened at $1.50 on Friday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 3.78 and a current ratio of 3.78. The firm has a market cap of $151.82 million, a price-to-earnings ratio of -1.29 and a beta of 0.99. Alector has a 1 year low of $0.87 and a 1 year high of $6.14. The firm’s 50 day moving average price is $2.77 and its two-hundred day moving average price is $1.89.

Institutional Investors Weigh In On Alector

A number of institutional investors have recently modified their holdings of ALEC. Bank of New York Mellon Corp boosted its stake in shares of Alector by 8.1% during the 1st quarter. Bank of New York Mellon Corp now owns 249,494 shares of the company’s stock valued at $307,000 after buying an additional 18,765 shares during the period. Cerity Partners LLC acquired a new stake in shares of Alector during the 1st quarter valued at $51,000. CWM LLC lifted its stake in shares of Alector by 370.7% in the 1st quarter. CWM LLC now owns 33,643 shares of the company’s stock valued at $41,000 after purchasing an additional 26,495 shares during the last quarter. Invesco Ltd. lifted its stake in shares of Alector by 209.6% in the 1st quarter. Invesco Ltd. now owns 148,576 shares of the company’s stock valued at $183,000 after purchasing an additional 100,591 shares during the last quarter. Finally, Nuveen LLC acquired a new stake in shares of Alector in the 1st quarter valued at $170,000. Institutional investors and hedge funds own 85.83% of the company’s stock.

Insider Activity

In other Alector news, Director Paula Hammond sold 14,000 shares of Alector stock in a transaction on Tuesday, August 26th. The shares were sold at an average price of $2.36, for a total transaction of $33,040.00. Following the completion of the sale, the director owned 74,909 shares of the company’s stock, valued at $176,785.24. This trade represents a 15.75% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 9.70% of the stock is owned by company insiders.

Alector Company Profile

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.